45062
document
The role of adjunctive exenatide therapy in pediatric type 1 diabetes . OBJECTIVE Exenatide improves postprandial glycemic excursions in type 2 diabetes . Exenatide could benefit type 1 diabetes as well . We aimed to determine an effective and safe glucose-lowering adjuvant exenatide dose in adolescents with type 1 diabetes . RESEARCH DESIGN AND METHODS Eight subjects completed a three-part double-blinded randomized controlled study of premeal exenatide . Two doses of exenatide ( 1.25 and 2.5 microg ) were compared with insulin monotherapy . Prandial insulin dose was reduced by 20 % . Gastric emptying and hormones were analyzed for 300 min postmeal . RESULTS Treatment with both doses of exenatide versus insulin monotherapy significantly reduced glucose excursions over 300 min ( P < 0.0001 ) . Exenatide administration failed to suppress glucagon but delayed gastric emptying ( P < 0.004 ) . CONCLUSIONS Adjunctive exenatide therapy reduces postprandial hyperglycemia in adolescents with type 1 diabetes . This reduction in glucose excursion occurs despite reduction in insulin dose . We suggest that exenatide has therapeutic potential as adjunctive therapy in type 1 diabetes .
45063
Intervention_Pharmacological
adjunctive exenatide therapy
45064
Intervention_Pharmacological
Exenatide
45065
Intervention_Pharmacological
Exenatide
45066
Intervention_Pharmacological
exenatide
45067
Intervention_Pharmacological
Two doses of exenatide ( 1.25 and 2.5 microg )
45068
Intervention_Pharmacological
insulin monotherapy
45069
Intervention_Pharmacological
insulin
45070
Intervention_Pharmacological
exenatide
45071
Intervention_Pharmacological
insulin monotherapy
45072
Intervention_Pharmacological
Exenatide
45073
Intervention_Pharmacological
exenatide
45074
Intervention_Pharmacological
exenatide
45075
Outcome_Physical
glycemic excursions
45076
Outcome_Physical
glucose-lowering
45077
Outcome_Physical
reduced glucose excursions
45078
Outcome_Physical
failed to suppress glucagon but delayed gastric emptying
45079
Outcome_Physical
reduces postprandial hyperglycemia
45080
Outcome_Physical
glucose excursion
45081
Participant_Age
pediatric
45082
Participant_Condition
type 1 diabetes .
45083
Participant_Age
adolescents
45084
Participant_Condition
type 1 diabetes
45085
Participant_Sample-size
Eight
45086
Participant_Age
adolescents